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Abstract
Prion diseases are characterized by the deposition of an abnormal form (termed PrP(Sc)) of the cellular
prion protein (PrP(C)). Because antibodies to PrP(C) can antagonize deposition of PrP(Sc) in cultured
cells and mice, they may be useful for anti-prion therapy. However, induction of protective anti-prion
immune responses in WT animals may be hindered by host tolerance. Here, we studied the cellular and
molecular basis of tolerance to PrP(C). Immunization of Prnp(o/o) mice with bacterially expressed PrP
(PrP(REC)) resulted in vigorous humoral immune responses to PrP(REC) and native cell-surface
PrP(C). Instead, WT mice yielded antibodies that failed to recognize native PrP(C) despite
immunoreactivity with PrP(REC), even after immunization with PrP-PrP polyprotein and/or upon
administration of anti-OX40 antibodies. Consequently, immunized WT mice experienced insignificantly
delayed prion pathogenesis upon peripheral prion challenge. Anti-PrP immune responses in Prnp(o/o)
mice were completely abrogated by transgenic expression of PrP(C) in B cells, T cells, neurons, or
hepatocytes, but only moderately reduced by expression in myelinating cells, despite additional thymic
Prnp transcription in each case. We conclude that tolerance to PrP(C) can coexist with immunoreactivity
to PrP(REC) and does not depend on thymic PrP(C) expression. Its circumvention might represent an
important step toward the development of effective anti-prion immunotherapy.
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Prion diseases are characterized by the deposition of an abnormal
form (termed PrPSc) of the cellular prion protein (PrPC). Because
antibodies to PrPC can antagonize deposition of PrPSc in cultured
cells and mice, they may be useful for anti-prion therapy. However,
induction of protective anti-prion immune responses in WT animals
may be hindered by host tolerance. Here, we studied the cellular
and molecular basis of tolerance to PrPC. Immunization of Prnpo/o
mice with bacterially expressed PrP (PrPREC) resulted in vigorous
humoral immune responses to PrPREC and native cell-surface PrPC.
Instead, WT mice yielded antibodies that failed to recognize native
PrPC despite immunoreactivity with PrPREC, even after immuniza-
tion with PrP-PrP polyprotein andor upon administration of anti-
OX40 antibodies. Consequently, immunized WT mice experienced
insignificantly delayed prion pathogenesis upon peripheral prion
challenge. Anti-PrP immune responses in Prnpo/o mice were com-
pletely abrogated by transgenic expression of PrPC in B cells, T cells,
neurons, or hepatocytes, but only moderately reduced by expres-
sion in myelinating cells, despite additional thymic Prnp transcrip-
tion in each case. We conclude that tolerance to PrPC can coexist
with immunoreactivity to PrPREC and does not depend on thymic
PrPC expression. Its circumvention might represent an important
step toward the development of effective anti-prion immunotherapy.
Prion diseases or transmissible spongiform encephalopathiesare lethal neurodegenerative disorders affecting many ani-
mal species. They include bovine spongiform encephalopathy of
cattle, chronic wasting disease of deer and elk, and Creutzfeldt–
Jakob disease in humans. The causative agent is termed prion (1)
and was proposed to be identical with PrPSc, a pathological
conformer of the cellular prion protein (PrPC) encoded by the
Prnp gene (2). PrPC is expressed on the surface of almost all cells
in the body, but at particularly high levels on neurons in the
peripheral and central nervous systems. PrPC is essential for the
development of prion disease, and Prnpo/o mice, which lack PrPC,
are resistant to scrapie (3).
Bovine spongiform encephalopathy (BSE) (4) is caused by
prions amplified through the bovine food chain (5). Transmis-
sion of bovine prions to humans has given rise to variant
Creutzfeldt–Jakob disease (vCJD) (6). Although the incidence
of BSE and vCJD may be stabilizing or even declining, the steep
rise of chronic wasting disease (7) underlines the fact that prion
diseases of farm and wild animals still represent a major threat.
Thus, there is an urgent and growing need for efficient prophy-
lactic andor therapeutic measures against prion diseases (8).
Although prions use immune and lymphoreticular cells to gain
access to the brain (9), several reports indicate that humoral
immune responses to the PrP can antagonize prion infection.
This is true even when such responses are directed primarily
against PrPC and do not selectively target PrPSc. mAbs and F(ab)
fragments recognizing PrP were shown to prevent de novo
scrapie infection and to abolish PrPSc as well as prion infectivity
in chronically scrapie-infected neuroblastoma cells (10). Further,
transgenic expression of anti-PrP antibodies in mice arrested
peripheral scrapie pathogenesis (11). In line with our results,
White and colleagues (12) confirmed the efficiency of anti-PrP
antibodies in preventing prion disease by injecting such antibod-
ies into WT mice upon peripheral prion challenge.
The prionostatic efficacy of anti-PrP antibodies is highest in
extraneural compartments: transgenic 6H4 mice expressing
anti-PrP-specific IgM molecules were not protected when prions
were administered intracerebrally (F.L.H. and A.A., unpub-
lished observations), and passive transfer of PrP-specific IgGs
(12) was inefficient when started after onset of clinical signs. This
finding may be caused by the limited influx of Igs into the CNS
and the high prion load of clinically symptomatic animals. By
providing stable, sustained titers, active immunization may
obviate to some of the problems listed above. However, host
tolerance to endogenous PrPC remains a major obstacle to
devising active immunization regimens. Nevertheless, several
recent studies suggest that the induction of anti-PrP antibodies
in WT mice is in principle feasible (13–18). Although anti-PrP
Ig titers could be measured in most of these studies, the titers
were rather low. Accordingly, the biological efficacy of these
immunization series, if evaluated at all, was limited, emphasizing
the need for alternative strategies.
The current study explores the efficacy of active immunization
strategies against PrP. We found that none of these strategies
leads to antibody titers to native cell-bound PrPC as displayed on
the cell surface of PrPC-overexpressing tg33 splenocytes (19).
This finding suggests that host tolerance to endogenous PrPC is
nonpermissive to generating high-affinity anti-PrP B cell clones
or leads to deletion or anergy of the cognate T cell clones. To
gain further insight into the mechanism of tolerance to PrP, a key
to defining successful immunization strategies against prions in
the future, we investigated the immune responses of transgenic
mice exhibiting expression of PrPC restricted to specific cell
types. Expression of PrPC within the thymus did not completely
prevent humoral immune responses to PrPREC. However, extra-
thymic and extraneural PrPC, even if expressed in very small
amounts, blocked all immune responses to both PrPC and
PrPREC. While antibodies recognizing cell-surface PrPC inter-
fered with prion pathogenesis in two independent paradigms, we
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found that humoral immune responses were not protective if
their affinity was restricted to PrPREC.
Methods
Mice. All mice were maintained under specific pathogen-free
conditions. WT mice F1 progeny of mixed background
C57BL6  129Sv were purchased from Harlan (Horst, The
Netherlands) to match the genetic background of Prnpo/o and
all of the transgenic mice used: CD-19-PrP [Tg431 or
Prnptm1-Tg(CD19-Prnp)431Zbz] (20), lck-PrP [Tg33 or
Prnptm1-Tg(lck-Prnp)191Zbz], albumin (Alb)-PrP [Tg01
or Prnptm1-Tg(Alb-Prnp)431Zbz] (19), and neuron-specific
enolase (NSE)-PrP [Tg1152 or Prnptm1-Tg(NSE-
Prnp)1152Zbz] (O. Giger, M. Glatzel, B. Navarro, and A.A.,
unpublished data). Myelin basic protein (MBP)-PrP [Tg640 or
Prnptm1-Tg(MBP-Prnp)640Zbz] transgenic mice express the
full PrP ORF (21) under the control of the MBP promoter.
Transgenic founders were mated to Prnpo/o mice, and one
transgenic line, designated tg640, was established from the F1
progeny on a Prnpo/o mixed background C57BL6  129Sv.
Further breeding yielded the homozygous line tg640/ or
MBP-PrP (22).
Recombinant Proteins. Generation of recombinant PrP-PrP
polyprotein has been described (23). PrP-PrP consists of a
tandem duplication of amino acids 23–231 of the murine PrP
lacking the N- and C-terminal signal peptides (amino acids 1–22
and 232–254, respectively). The PrP-PrP protein includes an
N-terminal polyhistidine tag that allows purification using a Ni2
column (23). Recombinant monomeric murine PrP (PrPREC)
was produced as described (24). Macrophage inhibitory factor
used as an ELISA control was expressed in bacteria by using a
similar method.
Immunization. For the initial injection, 100 g of recombinant
PrP-PrP polyprotein or PrPREC was emulsified in complete
Freund’s adjuvant (CFA) and injected s.c. The same amount of
protein emulsified in incomplete Freund’s adjuvant (IFA) was
used i.p. for boosting injections. Anti-OX40 antibody (100g per
injection) was injected i.p. three times after the first injection and
the first two boosts. The immunization protocol is shown in Fig.
1A. Serum samples were collected 14 days after each injection.
Prion Inoculation. Mice were inoculated i.p. with 100 l of brain
homogenate containing 103 LD50 infectious units of Rocky
Mountain Laboratory strain (passage 5.0) scrapie prions pre-
pared as described (9).
Anti-PrPREC Antibody Titer. ELISA to detect PrPREC-specific anti-
bodies was performed as described (11). Briefly, plates were
coated with 5 gml recombinant mouse PrP, washed with PBS
containing 0.1% (volvol) Tween 20 (PBST), and blocked with
5% BSA. After washing, plates were incubated with 30 l of
2-fold serially diluted serum (1:20 prediluted) in PBST contain-
ing 1% BSA and then probed with horseradish peroxidase-
conjugated rabbit anti-mouse (IgGAM, HL, or IgG 1:1,000
dilution, Zymed). Plates were developed with 2.2-azino-di-
ethyl-benzothiazolinsulfonate, and optical density was measured
at 405 nm. Titer was defined as the highest dilution showing an
OD more than two times the technical background, which was
calculated as the average of uncoated wells and wells incubated
omitting serum.
Anti-Native PrPC Antibody Titer. Splenocytes or blood cells derived
from transgenic tg33 mice overexpressing PrPC on T cells (19) were
incubated with serum derived from PrP-PrP- or PrPREC-
immunized mice or with monoclonal anti-PrP antibody ICSM 18 (a
kind gift of John Collinge, University College, London) as de-
scribed (11). Cells were washed and incubated with a FITC-labeled
anti-mouse IgG secondary antibody or FITC-labeled anti-mouse
IgM secondary antibody (Caltag Laboratories, Naenikon, Switzer-
land). Thereafter, cells were stained with phycoerythrin (PE)-
labeled anti-Thy 1.2 or PE-labeled anti-CD3 antibody for detecting
T cells. All antibodies were obtained from Becton Dickinson unless
otherwise indicated. Lysis of red blood cells was performed with
FACS lysing solution (Becton Dickinson). Living cells were gated
by using a combination of forward scatter and side scatter. Data
were acquired on a FACS Calibur (Becton Dickinson) with
CELLQUEST software (Becton Dickinson); postacquisition analyses
were performed with Windows Multiple Document Interface (WIN-
MDI, version 2.8, http:facs.scripps.edu).
Western Blotting. PrPREC (500 ng) or BSA as negative control
were loaded on an SDSPAGE and transferred onto a nitrocel-
lulose membrane. Strips containing one lane of PrPREC and one
of BSA were incubated with (i) a monoclonal anti-PrP antibody
(6H4, Prionics, Schlieren, Switzerland), (ii) preimmune serum of
a Prnp/ mouse, (iii) serum of an immunized Prnpo/o mouse,
and (iv) serum of an immunized Prnp/ mouse and subse-
quently, with horseradish peroxidase-conjugated rabbit anti-
mouse IgG antibody (Zymed). All sera were diluted 1:100 in
blocking buffer. For detection of PrPSc, brain homogenates of
prion-inoculated mice were prepared in PBS, 0.05% sodium
deoxycholate, and 0.05% Nonidet P-40. One part of each
homogenate was removed and digested with proteinase K (25
gml) to digest PrPC. Samples corresponding to 40 g of total
proteins ( proteinase K digestion) were loaded on an
SDSPAGE and transferred onto a nitrocellulose membrane
incubated with monoclonal anti-PrP antibody POM-1 (M.P.,
Martin Vey, and A.A., unpublished data) and horseradish
peroxidase (HRP)-conjugated rabbit anti-mouse IgG1 antibody
(Zymed). Blots were finally incubated with HRP substrate (ECL,
Pierce) and exposed on photosensitive film (Kodak).
Recall AssayCarboxyfluorescein (CFSE) Staining. Mice were immu-
nized with PrPREC or keyhole limpet hemocyanin (KLH; Sigma)
by s.c. injection of 200 g of the respective protein emulsified in
CFA. Seven days later, draining lymph nodes (inguinal and
axillary) were isolated and homogenized to a single cell suspen-
sion. To perform proliferation recall assays, cells were plated in
a 96-well plate at a density of 2  105 cells per well, which had
been coated with KLH or PrPREC, respectively, at a concentra-
tion of 50 gml before seeding cells. Twenty four hours later,
5 Ciml radioactive [3H]thymidine was added. Twenty four
hours later, cells were harvested, and radioactivity was measured
with a -counter system (1450 MicroBeta, PerkinElmer). CFSE
staining was accomplished by adding CFSE at a final concen-
tration of 10 M to lymph node cells that had been adjusted to
1.5 cells  107ml. Cells were incubated with CFSE for 10 min
at room temperature, avoiding bright light, washed once, and,
thereafter, cultured in 6-well plates (4  106 per well) in the
presence or absence of KLH or PrPREC, respectively at a
concentration of 50 gml. Four days later, cells were stained
with allophycocyanin (APC)-labeled anti-B220 (B cells), APC-
labeled anti-CD4 (T helper cells), or APC-labeled anti-CD8
(cytotoxic T cells) antibodies after one further washing step, and
FACS analysis was performed, as described above. All antibod-
ies were obtained from Becton Dickinson.
Isolation of Total RNA and Quantitative Real-Time RT-PCR. Thymi of
sex-matched 6- to 8-week-old mice were dissected, immediately
frozen in liquid nitrogen, and stored at 80°C until further use.
Total RNA was isolated by using a variable speed polytron
homogenizer and Trizol (Invitrogen) according to the manufac-
turer’s instructions and stored as an ethanolic precipitate at
20°C. Approximately 20 g of total RNA was processed for
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removal of contaminating genomic DNA (DNA-Free, Ambion,
Austin, TX). First-strand cDNA was synthesized by using 5 g
of DNase-treated RNA and NotI-oligo(dT) as primer in a 15-l
reaction volume according to the manufacturer’s instructions
(Amersham Pharmacia Biotech). In parallel, identical reactions
were prepared omitting the reverse transcriptase mix to allow
validation of complete removal of potentially contaminating
genomic DNA (-actin PCR, 40 cycles).
Assuming a 1:1 RNAcDNA conversion, 33.3 ng of first-
strand cDNA was used as template in real-time quantitative PCR
measurement of PrP RNA expression levels (Applied Biosys-
tems ABI Prism Sequence Detection System 7700) using
SybrGreen technology (PerkinElmer). Three mice of each ge-
notype were analyzed; each sample was measured in triplicate.
PrP expression levels were normalized to -actin values and
expressed as arbitrary values. All transgenic mice were on the
Zrch I Prnpo/o background (25), which express a PrP-neomycin
fusion transcript. Thus, the following primers were designed to
allow exclusive measurement of transgenic PrP RNA levels:
Prnp-F, 5-gctggccctctttgtgacta-3; Prnp-R, 5-ctgggcttgttccact-
gatt-3; actin-F, 5-gacggccaggtcatcactat-3; and actin-R, 5-
acatctgctggaaggtggac-3.
Fig. 1. Immunization of Prnp/ mice induces anti-PrPREC but not anti-PrPC responses and is not protective. (A) Mice were immunized three times with PrP-PrP
in 2-week intervals. Mice were then inoculated with prions i.p. (black arrow) and boosted with PrP-PrP every month until the first clinical signs of scrapie were
recorded. (B) Antibody titers to PrPREC were investigated by ELISA. Upon PrP-PrP immunization, Prnpo/o mice developed early and high anti-PrPREC titers, whereas
Prnp/ mice showed much lower titers at days 26–32 after immunization. (C) Specificity of measured titers. ELISA plates were coated with recombinant mouse
PrP (mPrP23–231), a truncated variant of it (mPrP121–231), or an unrelated recombinant protein produced by a similar method in E. coli. The results indicate that
antibodies were indeed directed to PrP rather than residual bacterial contaminants. MIF, Macrophage inhibitory factor. (D) Western blot using preimmune and
immune serum of Prnpo/o and Prnp/ mice and monoclonal anti–PrP antibody 6H4 for control. All strips were incubated with the same -mouse IgG secondary
antibody to allow comparison. Immune serum of both immunized mice specifically recognized PrPREC, but not BSA, which was loaded in the same amount as a
negative control. Preimmune serum of the same Prnp/ mouse showed no reactivity to PrPREC. (E) Survival plot visualizing incubation times until development
of terminal disease of immunized Prnp/mice after i.p. challenge with prions. Two immunized mice that received anti-OX-40 did not develop scrapie symptoms
until 585 days postinoculation, when they were killed. (F) Western blot analysis of brain homogenates of prion-inoculated immunized mice. The two mice that
displayed no signs of disease after580 days postinoculation showed no PrPSc accumulation in the brain. (G) Flow cytometric analysis of sera from immunized
mice on tg33 transgenic splenocytes with PrPC overexpression restricted to T cells. Cells were gated for live splenocytes and subsequently for CD3 T cells.
Histograms represent the intensity of the binding of anti-PrP antibodies present in sera of immunized mice. Serum of Prnpo/o mice at days 26 or 31 after
immunization showed specific recognition of native PrPC (Left). Instead, sera of immunized WT mice and preimmune sera did not recognize native PrPC (Right).
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Results
We used several immunization strategies to overcome tolerance
to PrPC. In a first set of experiments, mice were immunized with
bacterially expressed recombinant full-length PrP (PrPREC)
emulsified in CFA and IFA, respectively in combination with
anti-OX40 antibody (anti-CD134). This is an agonistic antibody
against the signaling molecule CD134, which recently has been
shown to break T cell tolerance (26). However, in contrast to
other reports (14), immunization using PrPREC in CFAIFA did
not result in measurable anti-PrPREC titers in WT mice in our
hands as assessed by ELISA. Additional administration of
anti-OX40 antibodies resulted in an insignificant increase of Ab
titers (data not shown).
A further immunization approach used a recombinant PrP-
PrP polyprotein emulsified in CFAIFA in combination with
anti-OX40 antibodies (Fig. 1 A), which had been previously
shown to elicit antibody responses in WT mice that cured
scrapie-infected neuroblastoma cells in vitro (23). Upon PrP-
PrPCFA immunization, WT mice displayed anti-PrPREC titers
as assessed by ELISA (Fig. 1B) and Western blot (Fig. 1D).
Titers were considerably lower than those of PrP-PrPCFA-
immunized Prnpo/o mice and were not augmented by anti-OX40
(Fig. 1B). Usage of an irrelevant Escherichia coli-derived protein
as ELISA substrate confirmed the specificity to PrPREC of the
respective sera (Fig. 1C).
To determine whether antibodies recognized native PrPC, sera
were added to splenocytes of tg33 mice, which transgenically
overexpress PrPC on T cells (19). Binding of serum Ig to native
PrPC was assessed by FACS as described (11). Whereas sera of
PrP-PrPCFA-immunized Prnpo/o mice strongly stained tg33
splenocytes, none of the WT sera contained antibodies recog-
nizing native PrPC regardless of the immunization method or
time point of analysis (Fig. 1G).
To determine whether the anti-PrP Abs produced upon
immunization were of any therapeutic value, we challenged
PrP-PrPCFA-immunized WT mice with scrapie prions by i.p.
injection of the Rocky Mountain Laboratory strain. Despite the
presence of substantial anti-PrPREC titers, immunized WT mice
did not exhibit significant delays in the onset of prion disease
(Fig. 1E), except for two of eight PrP-PrPCFA-immunized WT
mice that did not develop scrapie and, accordingly, did not
display measurable cerebral PrPSc at 585 days postinoculation
(Fig. 1F). This finding suggests that antibodies to PrPREC can be
induced in WT mice, yet these antibodies do not recognize native
PrP, do not interfere with scrapie pathogenesis, and may not be
of therapeutic value.
To test the latter hypothesis, we asked whether those anti-PrP
antibodies that were previously shown to interfere with prion
disease would recognize native PrPC on the surface of tg33 T
cells. We found that sera from 6H4 transgenic mice (carrying
the Prnpo/o, Prnp/o, or Prnp/ genetic background) showed
unambiguous binding to tg33, but not to Prnpo/o T cells (Fig. 2).
In addition, mAb ICSM18, which was shown to exert anti-prion
activity in vivo (12), reacted strongly with tg33 T cells (Fig. 1G).
These results add strength to the conjecture that binding to
native PrPC is crucial for anti-prion protection.
The above results point toward host tolerance as a crucial
barrier to the induction of functional anti-PrP immune re-
sponses. To understand the cellular requirements of tolerance to
PrPC, we investigated whether the tissue-specific distribution of
PrP determines the outcome of anti-PrP immunization. PrPC-
deficient (Prnpo/o) mice transgenically expressing PrPC exclu-
sively on B cells (20) or T cells (19) were immunized with mouse
PrPRECCFA. Expression of PrPC in either B or T cell compart-
ments sufficed to prevent generation of anti-PrPC titers inde-
pendent of the amount of PrPC expressed (Table 1). Even small
amounts of PrPC expressed solely on B cells in transgenic tg306
mice (20) completely inhibited the induction of anti-PrP titers
(Table 1).
To determine whether PrPC expression restricted to nonim-
mune cells would influence anti-PrP titers upon immunization
with PrPRECCFA, we used Prnpo/o mice transgenically express-
ing PrPC under the Alb promoter, which directs PrPC expression
to hepatocytes (Alb-PrP) (19). In addition, we immunized
Prnpo/o mice transgenically expressing PrPC in neurons under the
control of the NSE promoter (NSE-PrP; O. Giger, M. Glatzel,
B. Navarro, and A.A., unpublished data) or in oligodendrocytes
and Schwann cells driven by the MBP promoter (MBP-PrP) (22).
Whereas PrPREC immunization of MBP-PrP mice mounted
significant anti-PrPREC antibody titers, NSE-PrP and Alb-PrP mice
were unresponsive to immunizations similarly to WT mice (Fig.
3A). Further analysis revealed that anti-PrP antibodies of immu-
nized MBP-PrP mice consistently recognized native PrPC displayed
on tg33 T cells 28 days after immunization (Fig. 3B and Table 1).
In contrast, none of five PrPRECCFA-immunized WT mice, and
surprisingly also none of five NSE-PrP and five Alb-PrP mice
developed detectable anti-PrPC antibodies. Anti-PrP titers in
PrPREC-immunized MBP-PrP mice displayed delayed kinetics and
were reduced compared to Prnpo/o mice, suggesting that some
tolerogenic mechanisms were still operative.
To better understand these surprising differences in the immune
response of MBP-PrP, NSE-PrP, Alb-PrP, and control mice upon
PrPRECCFA immunization, a recall assay was performed. Lymph
node cells of PrPRECCFA-immunized transgenic and control mice
were rechallenged with PrPREC in vitro, and the proliferative
capacity of T and B cells was assessed. Whereas Prnpo/o lympho-
cytes exhibited vigorous proliferation, lymphocytes of WT, Alb-
PrP, and NSE-PrP mice did not proliferate, in agreement with their
inability to mount anti-PrPC titers in vivo. Instead, MBP-PrP mice
displayed moderate lymphocyte proliferation (Fig. 4A). These
differences were fully attributable to PrPREC-specific responses,
because a control antigen used in the same experiment (KLH)
induced similar lymphocyte proliferation in all investigated mice
(data not shown).
Next, CFSE-labeled B220 B cell, CD4 T helper, and CD8
cytotoxic T cell subsets were analyzed individually for their
proliferative capacity upon re-encountering PrPREC. B and
CD4 T helper lymphocyte subsets derived from MBP-PrP mice
displayed proliferative responses comparable to Prnpo/o lympho-
cytes, whereas CD8 cytotoxic T cells were only moderately
proliferative (Fig. 4 B and C). In contrast, Prnp/ lymphocytes
showed poor or no proliferative responses of B220 B cells and
CD8 cytotoxic T cells. Prnp/ CD4 T helper cells were
consistently nonresponsive (Fig. 4 B and C). The fact that few
B220 B cell displayed some proliferative capacity might ac-
Fig. 2. Sera from 6H4 transgenic mice react with PrPC on the surface of tg33
T cells. Scattergrams show representative FACS analyses of lymphocytes (tg33
or Prnpo/o) stained with mouse sera. 6H4 transgenic sera react with PrPC
overexpressing T cells (tg33; Upper), but not with Prnpo/o T cells (Lower). PrPC
gene dosage in 6H4mice correlates negatively with the extent of binding to
PrPC, suggesting the occurrence, to some extent, of clonal deletion of auto-
reactive B cells.
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count for the transient induction of scanty anti-PrP IgM anti-
bodies in a minority of PrPREC-immunized WT mice (data not
shown). Such anti-PrP IgM responses are short-lived and do not
mature to IgG antibodies (Fig. 3B and Table 1) most likely
because of the lack of T helper support. Thus, tolerance to PrPC
in WT mice appears to be mainly caused by an inadequate T
helper cell activation, as proposed (27).
To better understand why T helper cells of WT, NSE-PrP,
Alb-PrP, and, in part, MBP-PrP are tolerized to PrPC, we
investigated the level of thymic PrPC expression. Expression of
antigens within the thymus induces negative selection, i.e.,
deletion of self-reactive cells during T cell development, a
process known as central tolerance. PrPC protein was undetect-
able in the thymus of Alb-PrP and MBP-PrP mice (data not
shown). Prnp mRNA was detected by real-time RT-PCR in WT
and all transgenic lines, but mRNA levels were found to be
62-fold lower in Alb-PrP mice, 17-fold lower in MBP-PrP mice,
and 3.2-fold lower in NSE-PrP mice than in WT mice (Fig. 5).
Hence the levels of thymic PrP expression did not correlate with
the capability to mount anti-PrPC responses, suggesting that
tolerance to PrPC is primarily controlled extrathymically and is
only marginally affected by PrPC expression in myelinating cells.
Discussion
The original goal of this study was to assess the efficacy of PrPC
vaccination as an anti-prion strategy. Disappointingly, active
immunization of WT mice with various forms of bacterially
expressed recombinant PrP, even in the presence of a variety of
adjuvants, did not significantly interfere with prion disease
despite the generation of vigorous humoral immune responses to
bacterially expressed PrPREC. This result is in stark contrast to
the encouraging results obtained by transgenetic B cell repro-
gramming (11) and passive transfer (12) of anti-PrPC antibodies.
We then attempted to elucidate the characteristics discriminat-
ing protective vs. nonprotective immune responses. We reasoned
that a likely minimal prerequisite might be that protective
antibodies recognize the native eukaryotic form of PrPC as
expressed on the surface of cells. This hypothesis was analyzed
by establishing an assay in which transgenic tg33 T cells, which
overexpress PrPC under transcriptional control of the lck pro-
moter, were exposed to sera of immunized mice. Binding was
then assessed by quantitative cytofluorimetric analysis. Using
this assay, we found that sera of PrPREC-immunized WT mice did
not react with PrPC despite responses to PrPREC. In contrast, sera
from immunized Prnpo/o mice as well as sera from 6H4
transgenic mice (Fig. 2) and mAb ICSM18 (Fig. 1G), which was
shown to exert anti-prion activity in vivo (12), reacted strongly
with tg33 T cells. Therefore, the presence of anti-native PrPC
titers appears to correlate with the capability to interfere with
prion pathogenesis, and anti-native PrPC antibodies may repre-
sent an indispensable precondition for preventing prion diseases.
These findings may explain the very modest effects of active PrP
immunization attempts on prion pathogenesis that have been
reported by others (14) and should lead to a critical reassessment
of the value of immunization protocols, leading to immune
responses whose affinity to native PrPC has not been investigated
(13–18, 28).
What might be the molecular difference between antibodies
that only react to PrPREC and those that recognize PrPC?
Because bacterially expressed PrP lacks all glycosylation, the
Fig. 3. Antibodies to PrPREC and PrPC in immunized MBP-PrP transgenic mice. (A) PrPREC-specific antibody titers were investigated by ELISA at several time points
of immunization. No titer was detected in Prnp/, Alb-PrP, and NSE-PrP mice. Instead, MBP-PrP mice showed definite titers, although lower than those of Prnpo/o
mice (n 4–5). (B) Representative dot blots of mice of the indicated genotype, immunized with PrPREC in CFAIFA at day 14 (Upper) or day 28 of immunization
(Lower). When sera of MBP-PrP mice were used at day 14 after immunization, only a small fraction of Thy1.2 T cells seemed positive, whereas at day 28 the
majority of them shifted to the PrP-positive range.
Table 1. Transgenes, PrPC expression patterns, and anti-PrPC responses in mice immunized with PrPREC








ZH-I Prnpoo None Undetectable 3–4 3.2  1.68
WT C57BL6 Ubiquitous 100  15.9 0–1 1  0.12
Tg33 Lck-Prp T cells 7,705  428 0–1 0.42†
Tg306 CD19-PrP B cells Not done 0–1 0.35†
Tg01 Alb-PrP Hepatocytes 1.5  0.1 0–1 1.23†
Tg1152 NSE-PrP Neurons 28.9  6 0–1 0.87†
Tg640 MBP-PrP Oligodendrocytes and Schwann cells 5.5  1.3 2–3 1.3  0.58
*Relative to WT transcription (arbitrarily set to 100).
†n  2.
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differences may impinge on immunoreactivity to glycomoieties
linked to PrPC. However, this cannot fully account for the
discrimination between the two forms of PrP, as both the
ICSM18 mAb and serum from 6H4 transgenic mice recognize
the 19–21 core fragment of PrPSc, which is devoid of sugar
residues. Nor can discrimination be explained by the weaker
anti-PrP titers of PrPC-expressing mice, as Prnpo/o sera clearly
react with tg33 splenocytes even at dilutions yielding ELISA
signals similar to those of Prnp/ mice (data not shown).
Instead, Prnpo/o mice may develop low-affinity antibodies to
PrPC. Although such antibodies may bind to surface-immobilized,
arrayed PrPREC, where pure protein is concentrated in a very small
area, they may not show reactivity on a more ‘‘demanding’’ cell
surface microenvironment, where the target protein is present at
lower density. Alternatively, PrPC and PrPREC may differ in some
structural feature, a contention for which no physical evidence is
available, or the microenvironment of PrPC with its associated
proteins and lipids masksdistorts epitopes that are exposed in
PrPREC. Logically, such ‘‘pseudoautoimmune’’ responses to
epitopes that are nonexistent in vivo would be of little anti-prion
benefit. Antibodies that recognize both PrPC and PrPREC appear to
be more useful, at least in the case of ICSM18 and 6H4; yet our
attempts at such immune responses in WT mice were thwarted by
their strict tolerance to PrPC.
It follows from the above that understanding the tolerogenic
mechanisms preventing the generation of anti-native PrPC an-
tibodies in WT mice is an essential prerequisite to successfully
translating anti-PrPC vaccination into practice. Tolerance is
unlikely to be entirely caused by specific B cell tolerance: B cells
can be easily programmed to express anti-PrPC specificities in
mice expressing PrPC by transgenesis and are therefore permis-
sive for expression of autoreactive B cell receptors to PrPC,
unless PrPC is overexpressed at vastly supraphysiological levels
(11). Tolerance to PrPC appeared to be tightly regulated and
could not be overcome by the administration of stimulatory
anti-CD134 antibodies, which were shown to break existing T cell
tolerance in another model (26). Whereas two of eight anti-
CD134-treated, PrP polyprotein-immunized mice did not de-
velop scrapie upon prion inoculation, the remaining six CD134-
treated mice did not show a significant delay in the onset of prion
disease. While far from spectacular, these results suggest that the
combination of specific immunogens with CD134 stimulation
might marginally influence prion pathogenesis.
Because T helper cell assistance is crucial for mediating
adequate B cell responses, unresponsiveness or deletion of the
appropriate CD4 T cell clones is likely to contribute to the lack
of protective anti-PrP immune responses in immunized WT
mice. T cell tolerance to self-antigens is mediated by deletion of
autoreactive T cells in the thymus (central tolerance) as well as
by a regulatory control network active in the peripheral immune
compartment (peripheral tolerance).
The role of T cell tolerance was probed by immunizing
Prnpo/o mice that do not express any PrPC, as well as Prnpo/o
mice bearing transgenes that direct PrPC expression predom-
inantly to B cells (CD19-PrP and Ig-PrP) (20), T cells
(lck-PrP) (19), hepatocytes (Alb-PrP) (19), neurons (NSE-
PrP), or oligodendrocytes (MBP-PrP). In vitro recall chal-
lenges of lymphocytes after immunization showed that B and
T lymphocytes from Prnpo/o mice were fully responsive to
immunization, whereas expression of PrP by any of the trans-
genes studied prevented proliferative responsiveness, except
for MBP-PrP  Prnpo/o mice, which generated a measurable
PrPREC-specific lymphocyte response. These data closely cor-
relate with the generation of anti-PrPC-specific antibodies, as
only Prnpo/o mice, and to a lesser extent MBP-PrP mice,
developed measurable anti-PrPC humoral immune responses.
Expression of PrPC on B and T lymphocytes was obviously
expected to be tolerogenic, similar to what had been found in the
Fig. 5. Thymic PrP expression does not correlate with anti-PrP immune
responses. Thymic PrP mRNA levels of transgenic mice expressing PrPC under
cell-specific promoters, assessed by RT-PCR. Alb-PrP mice showed only traces of
PrP mRNA, whereas MBP-PrP showed moderate and NSE-PrP showed relatively
high levels of PrP mRNA.
Fig. 4. Cellular responses to PrPREC correlate with humoral responses. (A)
Thymidine incorporation into lymph node cells 48 h after in vitro restimulation
with PrPREC. Lymph node cells were taken from mice that had been immunized
with PrPREC in CFA 7 days earlier and were cultured for 48 h in the presence or
absence of PrPREC. The proliferation index represents the ratio of thymidine
incorporation of antigen-stimulated to unstimulated cells. Each symbol sum-
marizes triplicate cultures from one individual mouse (results from three
independent experiments). The dotted line represents a ratio of 1 and corre-
sponds to the thymidine incorporation of unstimulated cells. (B) CFSE stains
from lymph node cells of immunized Prnpo/o, Prnp/, and MBP-PrP mice 4
days after in vitro restimulation with PrPREC. Prnp/-immunized mice showed
poor or no proliferation of B220 (B cells) or CD8 (cytotoxic T cells) and totally
unresponsive CD4 (T helper cells), whereas Prnpo/o and MBP-PrP mice showed
comparable proliferation in B and CD4 T cells. CD8 T cells were only
moderately proliferative on some of the MBP-PrP mice. Proliferation index
represents the ratio of the percentage of proliferating PrPREC-stimulated cells
(lower CFSE intensity) to that of unstimulated cells. Results are of two inde-
pendent experiments (Prnpo/o and Prnp/ n  5, MBP-PrP n  6). (C) CFSE
stains from lymph node cells of immunized Prnpo/o, Prnp/, and MBP-PrP mice
4 days after in vitro restimulation with the antigen (PrPREC or KLH). One
representative mouse of each genotype is depicted.
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hen-egg lysozyme transgenic model (29). Less surprising, minute
PrPC expression levels in any extracerebral nonimmune com-
partment but myelinating cells prevented humoral anti-PrPC
immunity as well. To improve our understanding of the above
phenomena, we determined the thymic transcription levels of
Prnp in all PrP transgenic mice. Thymic PrP expression did not
appear to correlate well with the extent of tolerance, as MBP-PrP
thymi yielded stronger signals than Alb-PrP thymi.
Persistent self-antigen in extrathymic compartments can also
induce tolerance, and this is one of the mechanisms by which
peripheral tolerance is mediated. A compartment that has been
shown to be very efficient in conferring peripheral tolerance is
the liver (30), which is in line with the complete lack of anti-PrPC
responses in PrP-immunized Alb-PrP mice despite minimal
thymic PrP transcription. Although it is widely held that expres-
sion of tissue-specific antigens (TSAs) is excluded from the
thymus, thus precluding central tolerance, a recent report dem-
onstrates that few medullary epithelial cells within the thymus
express TSAs (31), a process that is genetically controlled by the
AIRE gene (32).
Although the development of anti-PrP antibodies recognizing
native PrPC in immunized MBP-PrP mice is encouraging, the
prionostatic potential of such antibodies cannot be tested di-
rectly because oligodendrocytes are intrinsically resistant to
prion infection (22). As B cells transgenically expressing an
anti-PrP  chain (6H4) in the presence of PrPC are not
intrinsically tolerant to PrPC (11), and thymic expression of PrPC
did not suffice to quench anti-PrPC antibody generation, neither
B cells nor thymic T helper deletion can fully account for host
tolerance to PrPC. Therefore, we infer that control by peripheral
T helper cells may constitute one of the limiting steps when
attempting to break tolerance in Prnp/ mice.
A recent study illustrated that anti-PrP antibodies upon direct
injection into the brain crosslink PrPC and provoke neuronal
death (33). This may theoretically represent a serious caveat to
PrP immunization approaches. However, none of the anti-PrP
mAbs used in that study had been shown to be prionostatic in
vivo, and anti-PrP antibodies were neurotoxic only at intracere-
bral concentrations that would be unlikely to be reached by
means of active immunization. Therefore, it would appear
premature to halt development of antibody-based anti-prion
strategies.
Disappointingly, active PrP immunization of WT mice with
bacterially expressed PrP moieties, such as PrPREC and PrP-PrP
polyprotein, in the presence of various adjuvants did not suffice
to effectively interfere with prion disease. Although WT mice
upon PrP immunization mounted anti-PrP antibodies, which
bound to recombinant PrP, the native form of PrPC was not
recognized. Along with the successful outcome of adoptive
antibody transfer experiments and antibody transgenesis, these
results suggest that effective anti-prion immunity may necessi-
tate anti-native PrPC titers. The difficulties involved in eliciting
development of such anti-PrPC immune responses may reside, at
least in part, in peripheral T helper tolerance. Thorough eluci-
dation of the basic mechanisms of such tolerance will be needed
to successfully and safely implement active vaccination as a
viable anti-prion regimen.
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